Paris polyphylla enhances the anti-metastatic efficacy of maimendong decoction against lung cancer Authors: Zhipeng Zhang, Jiaxuan Li, Wenfei Shi, Zujun Que, Wang Yao, Jialiang Yao, Wenji Shangguan, Weikang Zhu, Likun Liu, Jianhui Tian Published: 2025 ABSTRACT BackgroundMaimendong decoction (MMDD), a classic traditional Chinese medicine (TCM) formula prescribed for ‘lung atrophy’, has demonstrated efficacy against various pulmonary disorders. Our prior research confirmed that MMDD inhibit lung cancer metastasis by modulating natural killer (NK) cells. Paris polyphylla (P.P), a TCM herb with known anti-tumor properties, is often incorporated into classic formulas to enhance therapeutic outcomes. This study aimed to boost the anti-metastatic efficacy of MMDD against lung cancer by incorporating Paris polyphylla (Chonglou) and to investigate the underlying mechanisms.MethodsThe Modified Maimendong Decoction (MMDD + P.P) Was Prepared by Adding 9–18 g of Paris polyphylla. Its Effects on the proliferation, migration, and Apoptosis of CTC-TJH-01 and LLC Cells Were Assessed Using CCK-8, Transwell, and Annexin V-FITC/PI Flow Cytometry assays. Apoptosis-related Proteins Were Analyzed by Western blot. A Tail Vein injection-induced Lung Metastasis Model in C57BL/6 Mice Was Established To Evaluate the Effects of MMDD + P.P, both Alone and in Combination with an anti-PD-1 antibody, on MetastasisFlow cytometry was used to profile T cell and NK cell populations in peripheral blood. Histological and molecular analyses of metastatic tissues were performed using H&E staining, immunohistochemistry (for Ki-67 and cleaved caspase-3), and immunofluorescence (for CD8+ T cell and NK cell infiltration).ResultsCompared to MMDD alone, MMDD + P.P (18 g) significantly inhibited proliferation and migration, and induced apoptosis in both CTC-TJH-01 and LLC cells. These effects were associated with the upregulation of pro-apoptotic proteins (cleaved caspase-3, BAX, cleaved PARP) and downregulation of anti-apoptotic proteins (BCL-2, Survivin). In vivo, while both MMDD and MMDD + P.P reduced the number of lung metastatic nodules, MMDD + P.P (18 g) was uniquely effective in significantly reducing overall tumor burden, which correlated with decreased Ki-67 and increased cleaved caspase-3 in metastatic foci. Furthermore, MMDD + P.P (18 g) significantly increased the proportions and tumor-infiltration of NK cells and CD8+ T cells. It also synergized with anti-PD-1 therapy, enhancing its anti-metastatic effect and boosting the expression of cytotoxic markers (CD107a, perforin, granzyme B) and TNF-α in CD8+ T cells.ConclusionIncorporating Paris polyphylla into MMDD enhances its anti-metastatic efficacy through a dual mechanism: directly inducing apoptosis in lung cancer cells and amplifying anti-tumor immunity by increasing the abundance and cytotoxic function of CD8+ T cells. The synergy between MMDD + P.P and anti-PD-1 antibody therapy highlights the potential of this modified TCM formula as a promising adjunctive treatment for inhibiting lung cancer metastasis.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12575-025-00317-x.Keywords: Lung cancer, Metastasis, Maimendong decoction, Paris polyphylla, CD8+ t cells Introduction Lung cancer is the deadliest malignancy globally, with the highest incidence and mortality in China, showing a rising trend [1, 2]. Distant metastasis is responsible for approximately 90% of cancer-related deaths, representing a major therapeutic challenge [3]. Immunotherapy, particularly inhibitors targeting the PD-1/PD-L1 axis, has revolutionized cancer treatment, and its application has expanded from advanced disease to perioperative settings [4, 5]. For instance, pembrolizumab is approved as a first-line monotherapy for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression (CPS ≥ 1) based on the KEYNOTE-042 trial [6], and nivolumab is approved for second-line use based on CheckMate-017/057 [7]. Despite these advances, 20%–40% of patients with advanced NSCLC develop bone or brain metastases, and their median survival remains poor at only 4–6 months [8]. Therefore, improving the efficacy of immunotherapy and delaying the onset of resistance are critical challenges. Innate immune cells, such as NK cells, are rapidly activated to target cancer cells and play a significant role in controlling tumor dissemination and metastasis [9]. As a key component of adaptive immunity, CD8+ T cells are vital for anti-tumor immunity, particularly during tumor progression [10]. They mediate their effects through direct cytotoxicity (via the perforin-granzyme and Fas-FasL pathways), suppression of metastatic niches, and long-term immune surveillance via memory subsets. The functional integrity of CD8+ T cells—their activity, tumor infiltration, and cytokine secretion—is critical for tumor control and determines the efficacy of PD-1/PD-L1 inhibitors. Traditional Chinese medicine (TCM) offers a distinct advantage in modulating tumor immunity and often exhibits synergistic effects when combined with conventional therapy. Maimendong Decoction (MMDD), a classic formula from Jin Gui Yao Lue (Essential Prescriptions from the Golden Cabinet), is traditionally used for respiratory disorders such as cough, infections, bronchitis, asthma, and pulmonary fibrosis [11]. Our previous studies demonstrated MMDD inhibits lung cancer metastasis by regulating the proportion and function of NK cells [12]. However, in vitro assays revealed that MMDD alone does not significantly inhibit the proliferation and migration of lung cancer cells. This discrepancy underscores that the primary anti-metastatic mechanism of MMDD is immune-mediated rather than through direct cytotoxicity. Paris polyphylla, known as ‘Chonglou’ in TCM, is a well-documented medicinal herb with a long history of use in traditional formulas for treating ‘toxic swellings’ and tumors, as recorded in the classical compendium Bencao Gangmu. Modern pharmacological studies have identified steroidal saponins (e.g., polyphyllins I, II, VI, VII) as its key bioactive constituents, which exhibit significant anti-tumor effects against various malignancies, including lung, breast, and hepatocellular carcinoma [13]. Building upon this foundation, the present study incorporates Paris polyphylla—a herb renowned for its direct anti-tumor properties—into MMDD to create a modified formula (MMDD + P.P). We hypothesize that this combination will yield synergistic effects, enhancing direct tumor cell killing while simultaneously activating CD8+ T cell-mediated immunity. The findings are expected to support the clinical application of this modified formula, potentially improving strategies for the prevention and treatment of lung cancer metastasis. Materials and methods Cell Lines and Cell Culture The human CTC-TJH-01 cell line, derived from circulating lung tumor cells, was established in our laboratory [14, 15]. Murine Lewis lung carcinoma (LLC) cells were obtained from the Cell Bank of the Chinese Academy of Sciences. CTC-TJH-01 and LLC cells were cultured in F12K and DMEM media, respectively, each supplemented with 10% fetal bovine serum. All cells were maintained at 37 °C in a humidified atmosphere containing 5% CO2. Preparation of Modified Maimendong Decoction Plus Paris Polyphylla The modified Maimendong Decoction (MMDD+P.P) consisted of the following herbs: Ophiopogon japonicus (Thunb.) Ker Gawl. (42 g), Pinellia ternata (Thunb.) Makino (6 g), Glycyrrhiza uralensis Fisch (6 g), Panax ginseng C.A. Mey (9 g), Oryza sativa L. (6 g), 4 Ziziphus jujuba Mill, and Paris polyphylla Sm. (9 g or 18 g). All herbs were purchased from the Chinese Medicine Pharmacy of Shanghai Municipal Hospital of Traditional Chinese Medicine. To prepare the decoction, the herbs were soaked in 1000 ml of water for 30 minutes, decocted for 50 minutes, and the filtrate was collected. The residue was then soaked and decocted again in tap water for 40 minutes. The two filtrates were combined, concentrated by evaporation in a 70°C water bath, filtered, and lyophilized into a powder. The powder was stored at 4°C until use. UPLC-Q-TOF-MS Analysis of MMDD + P.P UPLC-Q-TOF-MS (ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry) was employed to identify and analyze the major chemical constituents of the MMDD + P.P (18 g) extract. Sample preparation involved dissolving 100 mg of the powdered extract in 1 ml of 70% methanol, vortexing for 1 min, adding steel beads, pre-cooling at −40 °C for 2 min, and homogenizing at 60 Hz for 2 min. Ultrasonic extraction was then conducted at 40 °C and 200 W for 60 min, followed by centrifugation at 12,000 rpm for 10 min. The supernatant was diluted 2-fold with 70% methanol-water, and 200 µl was transferred to an LC-MS vial for analysis. Chromatographic separation utilized an ACQUITY UPLC HSS T3 column (100 mm × 2.1 mm, 1.8 μm) with a mobile phase consisting of solvent A (0.1% formic acid in water) and solvent B (pure methanol). The gradient elution program was as follows: 0–2 min, 10%−20%; 2–15 min, 20%−50%; 15–20 min, 50–95%; 20–25 min, 95%−95%, at a flow rate of 0.35 ml/min. The injection volume was 2 µl, and the column temperature was maintained at 45 °C. Mass spectrometry was performed in both ESI positive and negative ionization modes. The spray voltage was set at 3200 V (negative) and 3800 V (positive), the capillary temperature at 320 °C, and the auxiliary gas heater temperature at 350 °C. The scan range was m/z 100–1500, and data were collected in both ionization modes. Drugs, Reagents and Antibodies The CCK-8 assay kit (#CX001M) was procured from Yeasen Biotechnology Co., Ltd. (Shanghai, China), while the crystal violet staining solution (#C0121) and Annexin V-FITC/PI apoptosis detection kit (#C1062M) were obtained from Beyotime Biotechnology Co., Ltd. (Shanghai, China). Antibodies against cleaved caspase-3, BAX, BCL2, Survivin, cleaved PARP, and GAPDH were acquired from Affinity Biosciences Pty Ltd (Cincinnati, OH, USA). The Ki-67 antibody (#27309-1-AP) was sourced from Proteintech (Wuhan, China). For flow cytometry analysis, the following antibodies were used: APC-NK1.1 (#108710), FITC-CD3 (#100220), PerCP/Cyanine5.5-CD8a (#100734), PE-CD4 (#100408), PE/Cyanine7-CD107a (#121620), PerCP/Cyanine5.5-granzyme (#150809), PE-perforin (#154305), PE-TNF-α (#506305), and PerCP/Cyanine5.5-IFN-γ (#505821), all purchased from BioLegend (Cambridge, UK). Recombinant anti-NK (#ab317504) and anti-CD8a (#ab316778) antibodies were procured from Abcam (Cambridge, UK). Cell-viability Assay CTC-TJH-01 and LLC cells were seeded in 96-well plates (2 × 104 cells/well) and treated with various concentrations (0, 62.5, 125, 250, 500, and 1000 µg/ml) of MMDD + P.P. After treatment, 10 µl of CCK-8 reagent was added to each well and incubated at 37 °C for 2 h. The optical density (OD) was then measured at 450 nm. Migration Assay Following treatment with MMDD + P.P (0, 250, and 500 µg/ml), CTC-TJH-01 and LLC cells were plated in the upper chambers of Transwell inserts, with the lower chambers containing 20% FBS-supplemented medium. After 24-hour incubation, the transwell inserts were carefully removed, air-dried, and subjected to fixation with 4% paraformaldehyde (30 min) followed by 0.1% crystal violet staining (30 min). After washing with PBS, the membranes were photographed under a microscope to evaluate invasive capability, and migrated cells were counted using Image J software. Cell Apoptosis Assay Following exposure to varying doses of MMDD + P.P (0, 250, and 500 µg/ml), CTC-TJH-01 and LLC cells were suspended in binding buffer for subsequent analysis. For apoptosis detection, cell suspensions were labeled with FITC-Annexin V (5 µl) and PI (10 µl), protected from light for 15 min, then subjected to flow cytometric analysis. Western Blot After 48-hour treatment with MMDD + P.P (18 g), cells from each group were collected, washed with PBS, resuspended in RIPA lysis buffer, and incubated on ice for complete lysis. Lysates were centrifuged to collect the supernatant (total protein), and the pellet was discarded. Following SDS-PAGE separation and PVDF membrane transfer, blots were blocked with 5% non-fat milk (1 h, RT) and subsequently probed with primary antibodies (manufacturer-recommended dilution) overnight at 4 °C. After washing, the membranes were probed with species-matched HRP-secondary antibodies for 1 h at room temperature. Protein signals were detected by ECL and quantified using Image J software, with GAPDH serving as the internal control. Relative expression levels of cleaved caspase-3, BAX, BCL2, Survivin, and cleaved PARP were compared across groups. Animal Seventy-two SPF-grade male C57BL/6 mice (5-week-old, 20 ± 2 g) were purchased from Shanghai KeLaiJiYin Biotechnology Co., Ltd. (Certificate No. SYXK (Hu) 2021-0012). All experimental protocols were approved by the Institutional Ethics Committee (SHDSYY-2023-T7885). Mice were housed in an AAALAC-accredited animal facility at Shanghai Tenth People’s Hospital under SPF conditions, with free access to autoclaved food and water. Lung Metastasis Model Establishment and Treatment For the first experiment, 30 mice were intravenously injected with LLC cells (3 × 105 cells in 100 µl per mouse) to induce lung metastasis, then randomly divided into 5 groups (n = 6): saline control, MMDD, MMDD + P.P (9 g), MMDD + P.P (18 g), and paclitaxel. Treatments were administered daily for 28 days via oral gavage: 0.2 ml saline, MMDD (1.98 g/kg), MMDD + P.P (9 g, 2.53 g/kg), or MMDD + P.P (18 g, 2.49 g/kg). Paclitaxel (5 mg/kg) was given intraperitoneally three times weekly for 1 month. For the second experiment, another 24 mice were injected with LLC cells (3 × 105 cells in 100 µl per mouse) and randomized into 4 groups (n = 6): saline control, MMDD + P.P (18 g), anti-PD-1, and MMDD + P.P (18 g) + anti-PD-1. Oral gavage (daily for 28 days) included 0.2 ml saline, or MMDD + P.P (18 g, 2.49 g/kg). Anti-PD-1 (7.5 mg/kg) was administered intraperitoneally three times weekly for 1 month. Visible metastatic nodules on the lung surface were counted under a dissecting microscope to evaluate metastatic burden in both experiments. Hematoxylin-eosin (H&E) Staining Tissue sections underwent xylene deparaffinization (10 min), followed by graded ethanol rehydration (2 min per step) and a 1-min distilled water rinse. Tissue sections were hematoxylin-stained (10 min), rinsed with tap water (1 min), and differentiated in 1% acid ethanol (30 s). Following tap water bluing, tissue sections underwent sequential processing through 95% ethanol (1 min), eosin counterstaining (0.5%, 3 min), graded ethanol dehydration (95–100%, 1 min per step), xylene clearing (I, II; 1 min each), and neutral balsam mounting. Sections were examined microscopically, and images were acquired. Metastatic foci were identified by morphological features: enlarged hyperchromatic nuclei, overlapping cellular arrangements, dense disordered architecture, and diffuse infiltrative growth. Neoplastic burden was calculated as (metastatic area/total organ area) × 100%. Immunochemistry (IHC) Paraffin sections were deparaffinized using routine methods, rinsed with distilled water, and incubated in PBS for 5 min. Endogenous peroxidase activity was quenched by immersion in deionized water for 10–15 min. After three PBS washes, sections were heated in 0.01% citrate buffer for 20 min, cooled to room temperature, and washed three more times with PBS (5 min each). Nonspecific binding was blocked with appropriate blocking serum for 15 min, followed by overnight incubation at 4 °C with primary antibody (1:100 dilution). Sections were washed three times with PBS (3 min each), incubated with secondary antibody at room temperature for 30 min, and rewashed with PBS. HRP-conjugated streptavidin working solution was then applied for 10 min at room temperature. Color was developed using DAB substrate, followed by rinsing with tap water. Slides were mounted and examined by light microscopy. Immunofluoresccence For antigen retrieval, lung metastasis samples were heated in citric acid buffer (90 °C, 10 min), blocked with 5% BSA (1 h), then incubated with primary antibodies against NK cells (ab317504, Abcam, 1:500) and CD8a (ab316778, Abcam, 1:500) overnight at 4 °C. After bleaching and washing, sections were mounted with anti-fluorescence quenching medium. Images were observed and captured under a fluorescence microscope. Flow Cytometric Analysis Anticoagulated blood (100 µl/mouse) collected via retro-orbital puncture was treated with 5 µl blocking reagent for 10 min at room temperature, then incubated with fluorochrome-conjugated antibodies (FITC-CD3, APC-NK1.1, PE-CD4, PerCP/Cy5.5-CD8) for 20 min at room temperature in the dark. Following erythrocyte lysis (1 ml buffer, 8 min) and centrifugation (350×g, 4 min), cells were washed twice with PBS and finally suspended in 300 µl of 1% BSA-PBS solution. The frequencies of CD8+ T cells and NK cells were quantified by flow cytometry. Network Pharmacology Analysis The target proteins of the 30 constituent compounds in MMDD + P.P. were predicted using tools such as SwissTargetPrediction [16]. Potential therapeutic targets associated with lung cancer and CD8+ T cells were further screened via disease databases including GeneCards and OMIM [17, 18]. Shared potential therapeutic targets between MMDD + P.P. components and lung cancer-related CD8+ T cells were identified using the Venny 2.1.0 platform, followed by visualization with a Venn diagram. A protein-protein interaction (PPI) network of potential anti-lung cancer targets for MMDD + P.P. was constructed using the STRING database [19]. Functional enrichment analysis of KEGG pathways was conducted using the Metascape bioinformatics platform [20]. Statistical Analysis All statistical analyses were conducted using SPSS version 23.0 (IBM Corp.). All data are presented as mean ± standard deviation (x̄ ± SD). Data normality was assessed through Shapiro-Wilk testing. Normally distributed variables were analyzed by one-way ANOVA with Bonferroni-corrected post hoc comparisons. Pearson correlation analysis was conducted to assess correlations. A p-value < 0.05 was considered statistically significant. Results Paris Polyphylla Enhances the anti-lung Cancer Efficacy of MMDD in Vitro Our previous studies have demonstrated that MMDD does not directly inhibit the proliferation of CTC-TJH-01 and LLC cells in vitro. However, it significantly suppresses lung cancer metastasis in vivo by increasing peripheral blood NK cell levels and promoting their infiltration into lung metastases [12]. To boost its therapeutic potential against lung cancer, we strategically augmented MMDD with Paris polyphylla and assessed the compound’s ability to suppress tumor cell proliferation and migration. CCK-8 assays showed that MMDD + P.P (18 g) significantly inhibited cell proliferation, with 48-h IC50 values of 45.99 µg/ml for CTC-TJH-01, and 165.9 µg/ml for LLC, respectively (Fig. 1A and B). In addition, transwell assays also revealed that MMDD + P.P (18 g) significantly suppressed migration of both cell lines, whereas MMDD alone and MMDD + P.P (9 g) had no effect (Fig. 1C and D). Furthermore, MMDD + P.P (18 g) significantly induced apoptosis compared to MMDD alone or its low-dose combination (Fig. 2A and B). It is noteworthy that the application of Paris polyphylla alone significantly inhibited the proliferation and migration of both CTC-TJH-01 and LLC cells, and induced apoptosis (Fig. S1). Mechanistically, MMDD + P.P (18 g) induction of apoptosis was associated with a dose-dependent increase in pro-apoptotic proteins (cleaved caspase-3, BAX, cleaved PARP) and a decrease in anti-apoptotic proteins (BCL-2, Survivin) (Fig. 2C). These results suggest that the addition of Paris polyphylla at doses of 18 g significantly enhances the inhibitory effects of MMDD on lung cancer cell proliferation and migration in vitro. Paris polyphylla augments the capacity of MMDD to suppress lung cancer cell proliferation and migration in vitro. (A-B) Cell viability of A CTC-TJH-01 and B LLC cells after 48 h treatment with MMDD or MMDD + P.P (9–18 g Paris polyphylla equivalents), determined by CCK-8 assay. (C-D) Migration capacity of C CTC-TJH-01 and D LLC cells after 48 h treatment, assessed by Transwell assay (representative images shown; crystal violet staining, 10× magnification). Data represent mean ± SD (n = 3 independent experiments). Statistical significance: ***P < 0.001 vs. untreated control; ###P < 0.001 vs. MMDD-only group Augmentation of MMDD with Paris polyphylla enhances apoptosis induction in lung cancer cells in vitro. (A-B) Apoptosis rates of A CTC-TJH-01 and B LLC cells after 48 h treatment with MMDD or MMDD + P.P (9–18 g Paris polyphylla equivalents), determined by Annexin V-FITC/PI double staining assay. C Western blot analysis of apoptosis-related proteins in CTC-TJH-01 and LLC cells treated with MMDD + P.P (18 g Paris polyphylla equivalent) at concentrations of 0, 100, and 200 µg/ml for 48 h. Data represent mean ± SD (n = 3 independent experiments). Statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001 vs. untreated control; ###P < 0.001 vs. MMDD-only group Paris Polyphylla Enhances the anti-metastatic Efficacy of MMDD in Vivo We next investigated whether supplementing MMDD with Paris polyphylla could enhance its anti-metastatic efficacy in vivo using a murine lung metastasis model. All treatment groups showed a reduction in the number of lung metastatic nodules compared to the saline control group; however, no significant difference in nodule count was observed between the MMDD + P.P groups and the MMDD-alone group (Fig. 3A). Treatments did not induce adverse effects, as evidenced by stable body weights and normal histology of vital organs (heart, liver, spleen, kidneys) across all groups (Fig. 3B and C). The effect of MMDD + P.P on inhibiting lung cancer metastasis in vivo. A Quantification of pulmonary metastatic nodules in C57BL/6 mice (n = 6/group) treated with: vehicle control, MMDD, MMDD + P.P (9–18 g Paris polyphylla equivalents), or paclitaxel (positive control, 5 mg/kg). B Comparison of body weights between each groups of C57BL/6 mice. C Representative hematoxylin and eosin (H&E) images of mouse cardiac, hepatic, splenic, and renal tissues (40 ×). Data represent mean ± SD (n = 6 independent experiments with 6 mice/group). Statistical significance: ***P < 0.001 vs. control; ###P < 0.001 vs. MMDD group Subsequently, we assessed the lung metastatic burden by H&E staining. The results demonstrated that MMDD + P.P (18 g) significantly reduced the metastatic burden compared to MMDD alone (Fig. 4A). Immunohistochemical analysis of metastatic nodules further revealed a marked upregulation of cleaved caspase-3 and a downregulation of Ki-67 in the MMDD + P.P (18 g) group, indicating enhanced apoptosis and suppressed proliferation (Fig. 4B and C). These findings suggest that the superior anti-metastatic effect of MMDD + P.P (18 g) is likely mediated through both the induction of apoptosis and inhibition of cancer cell proliferation. Augmentation of MMDD with Paris polyphylla enhances the inhibition of lung cancer metastasis in vivo. A Representative H&E-stained lung sections showing metastatic lesions (scale bar: 50 μm). B-C Immunohistochemical analysis of proliferative (Ki-67) and apoptotic (Cleaved Caspase-3) markers in metastatic foci (scale bars: 100 μm). Data represent mean ± SD (n = 3 independent experiments with 6 mice/group). Statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001 vs. control; #P < 0.05, ###P < 0.001 vs. MMDD group MMDD + P.P Modulates CD8+ T Cells and NK Cells We analyzed systemic and intra-tumoral immune responses in the mice. Both MMDD and MMDD + P.P significantly increased the proportion of NK cells in peripheral blood (Fig. 5A). In contrast to MMDD alone, the MMDD + P.P combination specifically expanded the CD3+CD8+ T cells population without affecting CD3+CD4+ T cells proportion (Fig. 5B and C). Immunofluorescence analysis of lung metastatic lesions confirmed that MMDD increased NK cell infiltration but had no significant effect on CD8 + T cells. Conversely, MMDD + P.P (18 g) significantly enhanced the infiltration of both NK cells and CD8 + T cells into the tumor microenvironment (Fig. 5D and E). These results indicate that the addition of Paris polyphylla (18 g) to MMDD specifically modulates the CD8+ T cell compartment, promoting its recruitment to metastatic sites. The immunomodulatory effects of MMDD + P.P on CD8+ T cells and NK cells. (A-C) Flow cytometric analysis of A NK cells, B CD8+ T cells, and C CD4+ T cells in peripheral blood of C57BL/6 mice. (D-E) Representative immunofluorescence images showing infiltration of D CD8+ T cells (red) and E NK cells (green) in lung metastatic lesions (scale bars: 100 μm; nuclei counterstained with DAPI in blue). Data represent mean ± SD (n = 6 independent experiments with 6 mice/group). Statistical significance: ***P < 0.001 vs. control group; #P < 0.05, ###P < 0.001 vs. MMDD group MMDD + P.P Enhances the anti-metastatic Efficacy of anti-PD-1 Antibody Given the immunomodulatory effects of MMDD + P.P on CD8 + T cells, we investigated its potential to synergize with anti-PD-1 therapy. We treated mice bearing lung metastases with MMDD + P.P (18 g), anti-PD-1 antibody, or their combination (Fig. 6A). All treatments were well-tolerated, as indicated by stable body weights (Fig. 6B). Compared to the saline control, MMDD + P.P (18 g), anti-PD-1 monotherapy, and the combination therapy all significantly reduced the number of lung metastatic nodules. Importantly, the combination therapy was significantly more effective than either treatment alone (Fig. 6C). We further analyzed the activity of circulating CD8+ T cells. Treatment with MMDD + P.P (18 g) significantly upregulated the expression of the degranulation marker CD107a, as well as the cytotoxic molecules granzyme B and perforin, and the cytokine TNF-α in CD8+ T cells, while IFN-γ levels remained unchanged (Fig. 6D-H). These findings demonstrate that MMDD + P.P (18 g) enhances the cytotoxic function of CD8 + T cells and acts synergistically with anti-PD-1 treatment to suppress lung cancer metastasis. MMDD + P.P synergizes with the anti-PD-1 monoclonal antibody to inhibit lung cancer metastasis. A Schematic of the experiment using traditional Chinese medicine combined with anti-PD-1 in mice. B Body weight changes of C57BL/6 mice (n = 6/group) during treatment, demonstrating treatment safety. C Quantitative analysis of pulmonary metastatic nodules in mice treated with: vehicle control, MMDD + P.P (18 g), anti-PD-1, or MMDD + P.P (18 g) + anti-PD-1 combination. (D-H) Flow cytometric analysis of cytotoxic markers in peripheral blood CD8+ T cells from treated mice: D CD107a (degranulation marker), E granzyme B, F perforin, and G TNF-α expression. H IFN-γ production by CD8+ T cells. Treatment groups included: vehicle control, MMDD + P.P (18 g Paris polyphylla equivalent) (n = 6/group). Data represent mean ± SD (n = 6 independent experiments with 6 mice/group). Statistical significance: **P < 0.01, ***P < 0.001 vs. control group; ns = not significant; ###P < 0.001 vs. anti-PD-1 monotherapy group Identification of Active Constituents in MMDD + P.P and Network Pharmacology Analysis UHPLC-MS/MS was employed to identify the active components in MMDD + P.P (18 g). Representative total ion chromatograms in ESI + and ESI − modes are shown in Fig. 7A and B, and characteristic compounds from each herb are listed in Table 1. Major compounds identified included glyasperin M, ipriflavone, liriopeside B, 20(S)-ginsenoside Rg3, malonylginsenoside Rd, and liquiritin. Compound identification in MMDD + P.P and network pharmacology analysis for the treatment of lung cancer. MMDD + P.P in ESI + mode A and ESI − mode B detect by UHPLC-MS/MS. C Venn diagram of common targets. D、F PPI network interaction diagram. E、G KEGG signal pathway enrichment analysis. BPC: Base Peak Chromatogram; Pos: Positive Ion Mode; NEG: Negative Ion Mode To elucidate the potential mechanisms underlying the anti-metastatic effects of MMDD + P.P, we performed a network pharmacology analysis. This analysis revealed 32 overlapping targets between MMDD + P.P and lung cancer (Fig. 7C), suggesting the involvement of PI3K-AKT and EGFR pathways in the direct inhibition of lung cancer cell proliferation, migration, and induction of apoptosis (Fig. 7D, E). From an immunological perspective, 22 core targets were common to MMDD + P.P, CD8⁺ T cells, and lung cancer (Fig. 7C; Table 2), including JAK2, JAK3, STAT3, and PIK3CA (Fig. 7F). KEGG enrichment analysis indicated that these targets were significantly associated with immune-related pathways, notably the JAK-STAT and PI3K-Akt signaling pathways (Fig. 7G). Collectively, these findings propose a putative dual mechanism whereby MMDD + P.P inhibits lung cancer metastasis by targeting the PI3K/Akt and EGFR pathways in cancer cells and modulating CD8 + T cell function via the JAK-STAT pathway, which warrants further experimental validation. Discussion This study demonstrates that incorporating Paris polyphylla (P.P) into Maimendong Decoction (MMDD) significantly enhances its anti-lung cancer efficacy through dual mechanisms of direct tumor suppression and immunomodulation. The modified formula, MMDD + P.P, not only exerted potent direct anti-proliferative and pro-apoptotic effects on lung cancer cells in vitro but also strongly inhibited metastatic progression in vivo. Crucially, the enhanced therapeutic outcomes were driven by the addition of Paris polyphylla, which endowed the formula with intrinsic tumor cell-killing capacity while simultaneously activating a robust anti-tumor immune response, specifically by modulating CD8 + T cells. Furthermore, MMDD + P.P significantly amplified the anti-metastatic effect of anti-PD-1 therapy, underscoring its potential as an immune-potentiating agent. Together, these findings establish Paris polyphylla as a critical component that augments the therapeutic profile of MMDD by synergizing direct cytotoxic effects with broad immune regulation. MMDD is a classical Chinese herbal formula from Jin Gui Yao Lue (Han Dynasty) and has been previously studied for its anti-lung cancer properties. Research has shown that MMDD, when combined with cisplatin, can regulate lncRNA-p21 [21], suppress the Wnt/β-catenin pathway via miR-149-3p [22], and inhibit A549 xenograft growth by modulating the PI3K/AKT pathway and inducing apoptosis [23]. Our prior research indicated that the anti-metastatic activity of MMDD in vivo is mediated by enhanced NK cell activity rather than a direct anti-proliferative effect on cancer cells, which was absent in vitro [12]. Paris polyphylla is widely used in traditional Chinese medicine for its anti-tumor, immune-enhancing, and anti-inflammatory properties. Its bioactive components, particularly polyphyllin saponins, have been shown to inhibit cancer cell proliferation and induce apoptosis in various tumor models [13]. The rationale for combining Paris polyphylla with MMDD lies in their complementary mechanisms: MMDD primarily modulates immune function (e.g., enhancing NK cell activity), aligning with the TCM principle of ‘reinforcing host defense’, while Paris polyphylla directly targets tumor cells through cytotoxic effects, embodying the concept of ‘pathogen elimination’. This combination reflects the TCM theory of ‘latent toxicity rooted in vital deficiency’, where MMDD strengthens the body’s resistance while Paris polyphylla attacks the disease. The dosages used in this study (9 g and 18 g) were determined based on clinical experience and the recommended range (15–30 g) for tumor therapy in Yunnan Chinese Herbal Medicine. Importantly, the addition of Paris polyphylla significantly improved MMDD’s efficacy, confirming its crucial role in enhancing anti-tumor activity. In vitro experiments demonstrated that MMDD + P.P (18 g) exhibits stronger anti-cancer effects than MMDD alone, including greater inhibition of cell proliferation, migration, and increased apoptosis induction. Previous studies have identified polyphyllin VI and VII as key bioactive compounds in Paris polyphylla with potent anti-tumor effects. These saponins induce G2/M cell cycle arrest and apoptosis in lung cancer cells by inhibiting PI3K/Akt and NF-κB signaling [24, 25]. Our preliminary work also found that polyphyllin VII suppresses lung cancer metastasis by inducing anoikis in circulating tumor cells (CTCs) via EGFR inhibition [26]. The anti-proliferative effect of MMDD + P.P (18 g) on lung cancer cells in vitro is primarily attributable to Paris polyphylla, a finding consistent with the efficacy observed when Paris polyphylla was used alone. In vivo, MMDD + P.P significantly reduced both lung metastatic nodules and overall tumor burden, while concurrently promoting apoptosis in cancer cells. Paclitaxel, despite inducing stronger early apoptosis and a rapid decrease in metastatic foci, paradoxically resulted in higher residual tumor burden. This discrepancy may arise from paclitaxel’s limited penetration into larger metastatic lesions, leading to incomplete eradication of surviving clusters that subsequently regrow. In contrast, MMDD + P.P, though exhibiting weaker initial apoptosis, demonstrated sustained suppression of metastatic progression over time. This delayed but potent effect likely stems from its dual mechanism: direct tumor cell killing combined with immunomodulatory actions—specifically, enhancing NK cell cytotoxicity and CD8+ T cell infiltration, which collectively constrain disseminated tumor cell survival and outgrowth. MMDD primarily inhibits metastasis by enhancing NK cell activity, whereas MMDD + P.P further amplifies this effect by increasing CD8+ T cell numbers in both peripheral blood and the tumor microenvironment. Paris polyphylla and its components have been shown to enhance CD8+ T cell infiltration and function. For example, polyphyllin VII upregulates CXCL9 and CXCL10, promoting CD8+ T cell recruitment to tumors [27], while polyphyllin I enhances anti-tumor immunity by inducing ferroptosis and boosting CD8+ T cell activity [28]. Similarly, paclitaxel enhances CD8+ T cell responses by inducing immunogenic cell death, thereby improving anti-PD-1/PD-L1 therapy efficacy [29, 30]. These findings suggest that Paris polyphylla enhances the anti-lung cancer metastasis effects of MMDD, primarily through directly inducing apoptosis of lung cancer cells and modulating the activation of CD8+ T cells. CD8+ T cells play a central role in anti-tumor immunity through cytotoxic mechanisms such as degranulation (CD107a), granzyme B/perforin-mediated killing, and cytokine secretion (IFN-γ, TNF-α). Impaired CD8+ T cell function contributes to tumor immune evasion and metastasis [31]. Our study found that MMDD + P.P enhances PD-1 blockade by improving CD8+ T cell function—increasing their numbers, cytotoxic markers (CD107a, granzyme B), and pro-inflammatory cytokine production (TNF-α). These results align with other TCM studies showing that herbal formulas can enhance CD8+ T cell responses to improve anti-tumor immunity [32–34]. Mechanistically, Paris polyphylla may modulate CD8+ T cells via the JAK-STAT and PI3K/Akt pathways, which regulate T cell activation, proliferation, and effector function. Network pharmacology analysis suggests that key components in MMDD + P.P (e.g., polyphyllin II, magnoflorine, ginsenoside Rg3) may synergistically target these pathways, further enhancing immune-mediated anti-tumor effects. Despite demonstrating the antimetastatic potential of MMDD combined with Paris polyphylla (MMDD + P.P), this study has several limitations warrant further investigation. First, the exclusion of other myeloid populations (e.g., macrophages and dendritic cells) represents a significant constraint, given their established roles as critical regulators of immune activation and suppression. Second, the immune profile in peripheral blood may not fully recapitulate the immune status within the tumor microenvironment (TME), including the extent of lymphocyte infiltration and activation—a well-recognized limitation in immuno-oncology research. Third, the specific bioactive compounds in Paris polyphylla responsible for the observed effects remain uncharacterized, leaving the pharmacological basis of its efficacy incompletely understood. These limitations will be explicitly addressed in our future mechanistic and experimental studies. Conclusions In conclusion, our findings demonstrate that the incorporation of Paris polyphylla into Maimendong Decoction significantly augments its anti-cancer efficacy through a multifaceted mechanism. The modified formula, MMDD + P.P, directly inhibits lung cancer cell proliferation, migration, and survival in vitro, and potently suppresses metastatic progression in vivo. Beyond these direct cytotoxic effects, the addition of Paris polyphylla critically enhances the immunomodulatory capacity of MMDD by promoting the infiltration and boosting the cytotoxic function of CD8+ T cells. This immunostimulatory effect underlies the observed synergy between MMDD + P.P and anti-PD-1 therapy, leading to superior inhibition of metastasis. These results provide a robust scientific rationale for the clinical application of MMDD + P.P as a promising adjunctive therapy. Its dual mechanism of action—simultaneously targeting tumor cells and amplifying anti-tumor immunity—positions it as a compelling strategy to improve metastatic control in lung cancer patients, particularly in combination with immune checkpoint inhibitors. Supplementary Information Supplementary material 1. Supplementary material 2. Acknowledgements Not applicable. Abbreviations Maimendong Decoction natural killer Paris polyphylla modified Maimendong decoction with Paris polyphylla Hematoxylin and eosin non-small cell lung cancer Traditional Chinese medicine Lewis lung carcinoma fetal bovine serum propidium iodide Immunochemistry protein-protein interaction tumor-infiltrating lymphocytes Authors’ Contributions Zhang. Z., Li. J., Shi. W. drafted the manuscript. Que. Z. supervised and revised the manuscript. Yao. W. conducted the experimental verification. Yao. J. contributed to the animal experiment. Shangguan. W. assisted in conceptualization. Zhu. W., Liu. L., Tian. J. administrated funding and revised the manuscript. All the authors contributed to the study and approved the final manuscript. Funding This study was supported by National Natural Science Foundation of China (82174245), Shanghai Frontier Research Base of Disease and Syndrome Biology of Inflammatory Cancer Transformation (2021KJ03-12), Shanghai Municipal Health Leading Talents Program (2022LJ014). National TCM Advantageous Specialty Construction Project of the National Administration of Traditional Chinese Medicine (Oncology Department-2024-510). Funded by the Key Specialty Development Project of Baoshan Branch, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (rbzdzk-2023-002). Data Availability Data will be made available on request. Declarations Consent for Publication Not applicable. Competing Interests The authors declare no competing interests. Ethical Approval and Consent To Participate All animal experiments followed the regulations of the Experimental Animal Ethics Committee of Shanghai Tenth People’s Hospital and approved (Ethics number: SHDSYY-2023-T7885). Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Zhipeng Zhang, Jiaxuan Li and Wenfei Shi contributed equally as the first authors to this work. Contributor Information Weikang Zhu, Email: zwkzl5k1016@163.com. Likun Liu, Email: llkun133@126.com. Jianhui Tian, Email: tjhhawk@163.com. References Associated Data Supplementary Materials Supplementary material 1. Supplementary material 2. Data Availability Statement Data will be made available on request.